India Compulsory Licensing: What USTR Hearing Transcripts Say
Executive Summary
Private assurances or not, the prickly debate around the use of compulsory licenses in India appears to have an ongoing subtext going by the transcript of statements by the US-India Business Council (USIBC) before the United States Trade Representative (USTR) at the 2016 Special 301 review public hearing.
You may also be interested in...
Pharma sees red as India allows Natco to produce patented Nexavar at 3% of Bayer's price
India has approved its first ever compulsory licence in the area of medicines for Bayer's anticancer Nexavar (sorafenib tosylate), allowing the domestic firm Natco Pharma, to self manufacture and sell a version of Nexavar for just over 3% of the price that Bayer sells the drug for in India.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.